Fundraising Fox
Enlaza Therapeutics
San Diego, US · Founded 2020 · 68 employees on LinkedIn · 9 known investors
Find your way into Enlaza Therapeutics
Sign up to see every warm intro you have to Enlaza Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Enlaza Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets. The company applies this synthetic biology platform to engineer biologics with improved efficacy and safety for treating cancer and other serious diseases.
Founders & leadership
Enlaza Therapeutics was founded in 2020 by Sergio Duron and Sanford Madigan.
Board
Investors · 9
How we know: the company's own site · Frazier Life Sciences's portfolio page · board seat on SEC Form D · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the company's own site · Lightspeed Venture Partners's portfolio page · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · the company's own site · board seat on SEC Form D · funding news · Not right? Tell us
How we know: Avalon BioVentures's portfolio page · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$134.3M disclosed across 3 of 7 rounds · 2021–2025
▶$15MraisedSep 2025 · 1 investors · PharmaceuticalsRule 506(b)
- Marcos MillaDirector
- Stephen SquintoDirector
- Tighe ReardonExecutive Officer
- Jay LichterDirector
- Shelley ChuDirector
- Sergio DuronExecutive Officer, Director
- James TopperDirector
- Sanford MadiganExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$84MraisedAug 2024 · 16 investors · PharmaceuticalsRule 506(b)
- Marcos MillaDirector
- Jay LichterDirector
- Sergio DuronExecutive Officer, Director
- Tighe ReardonExecutive Officer
- James TopperDirector
- Stephen SquintoDirector
- Sanford MadiganExecutive Officer
- Shelley ChuDirector
- Offering amount
- $110M
- Amount sold
- $84M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$35.3MraisedNov 2022 · 10 investors · PharmaceuticalsRule 506(b)
- Sanford MadiganExecutive Officer
- James TopperDirector
- Jay LichterDirector
- Shelley ChuDirector
- Tighe ReardonExecutive Officer
- Marcos MillaDirector
- Sergio DuronExecutive Officer, Director
- Offering amount
- $61.3M
- Amount sold
- $35.3M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶Undisclosed amountofferedOct 2022 · 1 investors · PharmaceuticalsRule 506(b)
- James TopperDirector
- Sergio DuronExecutive Officer, Director
- Jay LichterDirector
- Sanford MadiganExecutive Officer
- Marcos MillaDirector
- Shelley ChuDirector
- Tighe ReardonExecutive Officer
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$312KofferedOct 2022 · 1 investors · PharmaceuticalsRule 506(b)
- James TopperDirector
- Tighe ReardonExecutive Officer
- Shelley ChuDirector
- Sergio DuronExecutive Officer, Director
- Sanford MadiganExecutive Officer
- Marcos MillaDirector
- Jay LichterDirector
- Offering amount
- $312K
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶Undisclosed amountofferedAug 2021 · 1 investors · PharmaceuticalsRule 506(b)
- James TopperDirector
- Sergio DuronExecutive Officer, Director
- Marcos MillaDirector
- Sanford MadiganExecutive Officer
- Jay LichterDirector
- Shelley ChuDirector
- Tighe ReardonExecutive Officer
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶Undisclosed amountofferedJun 2021 · 1 investors · PharmaceuticalsRule 506(b)
- Shelley ChuDirector
- Tighe ReardonExecutive Officer
- Sanford MadiganExecutive Officer
- Sergio DuronExecutive Officer, Director
- Marcos MillaDirector
- James TopperDirector
- Jay LichterDirector
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Enlaza Therapeutics do?
- Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets. The company applies this synthetic biology platform to engineer biologics with improved efficacy and safety for treating cancer and other serious diseases.
- Who founded Enlaza Therapeutics?
- Enlaza Therapeutics was founded by Sergio Duron, Sanford Madigan in 2020.
- Who are Enlaza Therapeutics's investors?
- Enlaza Therapeutics's investors include Frazier Life Sciences, Lightspeed Venture Partners, Samsara BioCapital, Avalon BioVentures, Pappas Capital, Pfizer Venture Investments, J.P. Morgan Asset Management, OrbiMed.
- How much funding has Enlaza Therapeutics raised?
- Enlaza Therapeutics has disclosed $134.3M raised across 3 of its 7 known rounds.
- Where is Enlaza Therapeutics headquartered?
- Enlaza Therapeutics is headquartered in San Diego, US.